The city of Rochester, New York, currently has 4 active clinical trials seeking participants for Parkinson's Disease research studies.
A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Recruiting
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 50-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway. Participants will: • Take NEU-411 or placebo every day for 52 weeks
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
05/19/2025
Locations: University of Rochester, Rochester, New York
Conditions: Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
Community Outreach for Palliative Engagement -- Parkinson Disease
Recruiting
The purpose of this study is to learn more about the effectiveness of palliative care training for community physicians and telemedicine support services for patients and carepartners with Parkinson's disease and Lewy Body Dementia (LBD) or related conditions and their care partners. Palliative care is a treatment approach focused on improving quality of life by relieving suffering in the areas of physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and sp... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
05/13/2025
Locations: University of Rochester Medical Center for Health + Technology, Rochester, New York
Conditions: Parkinson Disease Dementia, Parkinson Disease, Parkinson's Disease and Parkinsonism, Lewy Body Parkinsonism, Dementia With Lewy Bodies, Progressive Supranuclear Palsy, Corticobasal Degeneration, Multiple System Atrophy, Vascular Parkinsonism
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
Recruiting
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
03/28/2025
Locations: University of Rochester, Rochester, New York
Conditions: Parkinson Disease
DB RCT for Specialized Phototherapy in Parkinson's Disease.
Recruiting
This is a pivotal study to determine whether light therapy can improve non-motor and motor function in Parkinson's disease, on top of current best medical treatment.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
04/19/2024
Locations: University of Rochester, Rochester, New York
Conditions: Parkinson Disease